Slingshot members are tracking this event:

Phase 2 updated data of Blueprint Medicines' (BPMC) Avapritinib BLU-285 - PIONEER trial in Indolent and smoldering systemic mastocytosis (SM) due at the AAAAI Annual Meeting March 14, 2020

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
BPMC Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Avapritinib, Blu-285, Smoldering Systemic Mastocytosis, Indolent Systemic Mastocytosis